Immunosuppression involving increased myeloid‑derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer

Suzuki,Shinichi; Shibata,Masahiko; Gonda,Kenji; Kanke,Yasuyuki; Ashizawa,Mai; Ujiie,Daisuke; Suzushino,Seiko; Nakano,Keiichi; Fukushima,Toshihiko; Sakurai,Kenichi; Tomita,Ryouichi; Kumamoto,Kensuke; Takenoshita,Seiichi

doi:10.3892/mco.2013.170

Immunosuppression involving increased myeloid‑derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer

Authors:
- Shinichi Suzuki
- Masahiko Shibata
- Kenji Gonda
- Yasuyuki Kanke
- Mai Ashizawa
- Daisuke Ujiie
- Seiko Suzushino
- Keiichi Nakano
- Toshihiko Fukushima
- Kenichi Sakurai
- Ryouichi Tomita
- Kensuke Kumamoto
- Seiichi Takenoshita
View Affiliations

Affiliations: Department of Thyroid and Endocrinology, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Tumor and Host Bioscience, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan, Department of Surgery, Nippon Dental University, Tokyo 102-8158, Japan
Published online on: August 22, 2013 https://doi.org/10.3892/mco.2013.170
Pages: 959-964

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive neoplasms in humans and myeloid‑derived suppressor cells (MDSCs) contribute to the negative regulation of immune responses in the context of cancer and inflammation. In order to investigate the pathophysiology of thyroid cancer, peripheral blood mononuclear cells (PBMCs) were obtained from 49 patients with thyroid cancer, 18 patients with non‑cancerous thyroid diseases and 22 healthy volunteers. The MDSC levels were found to be higher in patients with any type of thyroid cancer (P<0.05), patients with ATC (P<0.001) and patients with medullary thyroid carcinoma (P<0.05), when compared to patients with non‑cancerous thyroid diseases. The MDSC levels were also higher in patients with stage III‑IV thyroid cancer compared to those in patients with non‑cancerous thyroid diseases (P<0.05). The stimulation index (SI) of phytohemagglutinin (PHA)‑induced lymphocyte blastogenesis was significantly lower, the C‑reactive protein (CRP) levels were significantly higher and the serum albumin levels were significantly lower in patients with ATC compared to those in patients with non‑cancerous thyroid diseases. The SI was significantly lower in stage III and IV thyroid cancer compared to that in non‑cancerous thyroid disease (P<0.05). Furthermore, the CRP levels were higher and the concentration of albumin was lower in stage IV thyroid cancer compared to those in non‑cancerous thyroid disease (P<0.05). Patients with thyroid carcinoma were then classified into one of two groups according to a %PBMC of MDSC cut‑off level of 1.578, which was the average %PBMC of MDSC of patients with any type of thyroid carcinoma. In patients with higher MDSC levels, the production of CRP and interleukin (IL)‑10 was significantly higher (P<0.05) and the albumin levels were significantly lower (P<0.05) compared to those in patients with lower MDSC levels. These data indicate that MDSCs are increased in patients with ATC. Furthermore, these patients exhibited suppression of cell‑mediated immune responses, chronic inflammation and nutritional impairment.

View Figures

View References

1.	Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ and MacFarlane GJ: The epidemiology of thyroid carcinoma. Crit Rev Oncog. 4:25–52. 1993.
2.	Reeve TS and Delbridge L: Thyroid cancers of follicular cell origin. Prog Surg. 19:78–88. 1988.
3.	De Groot LJ, Kaplan EL, McCormick M and Straus FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 71:414–424. 1990.PubMed/NCBI
4.	Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA and Ordonez NG: The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1,599 patients. J Clin Endocrinol Metab. 75:714–720. 1992.PubMed/NCBI
5.	Franssila KO: Prognosis of thyroid carcinoma. Cancer. 36:1138–1146. 1975. View Article : Google Scholar
6.	Ain KB: Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 8:715–726. 1998. View Article : Google Scholar : PubMed/NCBI
7.	Giuffrida D and Gharib H: Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 11:1083–1089. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med. 10:909–915. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Pardoll D and Allison J: Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 10:887–902. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Gabrilovich DI and Nagaj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A and Ochoa AC: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:3044–3048. 2005.PubMed/NCBI
13.	Ochoa AC, Zea AH, Hernandez C and Rodriguez PC: Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 13:721s–726s. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Diaz-Montero CM, Salem ML, Nishimura MI, Garett-Mayre E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar
15.	Gabitass RF, Annels NE, Crawshaw J, Pandha HS and Middleton GE: Use of gemcitabine-(GEM) and fluoropyrimidine-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophago-gastric cancer (EGC) (abs. 2588). In: Proceedings of the 2011 Annual meeting of Am Soc Clin Oncol; 3–7 June 2011; Chicago
16.	Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H and Takenoshita S: Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoalbuminemia in patients with cancer. Oncol Rep. 28:453–458. 2012.PubMed/NCBI
17.	Moore KW, de Waal Malefyt R, Coffmann RL and O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Blackwill F and Mantovani A: Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 87:401–406. 2010. View Article : Google Scholar
19.	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Enomoto T, Sugawa H, Inoue T, Miyamoto M, Kosugi S, Takahashi T, Kitamura N, Yamamoto I, Konishi J, Mori T and Imura H: Establishment of a human undifferentiated human thyroid carcinoma cell line producing several growth factors and cytokines. Cancer. 65:1971–1979. 1990. View Article : Google Scholar
21.	Iwasa K, Noguchi M, Mori K, Ohta N, Miyazaki I, Nonomura A, Mizukami Y, Nakamura S and Michigishi T: Anaplastic thyroid carcinoma producing the granulocyte colony stimulating factor (G-CSF): report of a case. Surg Today. 25:158–160. 1995. View Article : Google Scholar : PubMed/NCBI
22.	Murabe H, Akamizu T, Kubota A and Kusaka S: Anaplastic thyroid carcinoma with prominent cardiac metastasis accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum. Intern Med. 31:1107–1111. 1992. View Article : Google Scholar
23.	Allin KH, Bojesen SE and Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 27:2217–2224. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Chen HH, Chen IH, Liao CT, Wei FC, Lee LY and Huang SF: Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 36:147–153. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterifield S and Kritchevsky SB: Circulating levels of inflammatory markers and cancer risk in the health aging and body comparison cohort. Cancer Epidemiol Biomarkers Prev. 14:2413–2418. 2005.PubMed/NCBI
26.	Erlinger TP, Platz EA, Rifai N and Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA. 291:585–590. 2004. View Article : Google Scholar : PubMed/NCBI
27.	Kao J, Ko EC, Eisenstein S, et al: Targeting immune suppressing myeloid-derived suppressor cells in oncology. Cri Rev Oncol Hematol. 77:12–19. 2011. View Article : Google Scholar : PubMed/NCBI